[
  {
    "question": "70 YO Alzheimer's Disease, started to get lost when going out, forget appointments, as he can not do daily activities. What to give.",
    "option_a": "Reassurance",
    "option_b": "Donepezil",
    "option_c": "vitamin E",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline that significantly interferes with daily functioning. Cholinesterase inhibitors, such as donepezil, are the cornerstone of symptomatic treatment in mild to moderate AD. AD is marked by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain, leading to the loss of cholinergic neurons. Donepezil works by inhibiting acetylcholinesterase, thereby increasing the availability of acetylcholine and helping to alleviate some of the cognitive symptoms associated with AD. In elderly patients exhibiting symptoms such as getting lost, forgetfulness, and inability to perform daily activities, a diagnosis of AD should be considered. Cognitive impairment, particularly in memory and executive function, correlates with the cholinergic deficits observed in AD. Donepezil may help improve or stabilize these symptoms temporarily. The clinical diagnosis of AD is based on the history, cognitive testing (e.g., MMSE, MoCA), and imaging studies to rule out other causes of dementia. Differential diagnoses include vascular dementia, frontotemporal dementia, and reversible causes like hypothyroidism or vitamin deficiencies. Neuropsychological testing is crucial for establishing the diagnosis. First-line treatment for mild to moderate AD is typically a cholinesterase inhibitor, with donepezil being the most commonly prescribed. Second-line options include other cholinesterase inhibitors (rivastigmine, galantamine) and memantine for moderate to severe cases. As AD is rare in pregnancy and lactation, specific guidelines for these populations are usually not applicable; however, in younger patients with early-onset AD, careful risk-benefit analysis and consultation with specialists is necessary. Option A (Reassurance) is inadequate given the progressive nature of AD. Option B (Donepezil) is correct as it directly addresses the symptomatic cholinergic deficit in AD. Option C (Vitamin E) has been investigated in AD but does not have robust evidence to support its routine use and carries risks at high doses. Option D is not provided. 1. Donepezil is the most commonly used first-line cholinesterase inhibitor in AD. 2. Early intervention in AD can help slow the progression of cognitive decline. 3. Regular cognitive assessments are essential to monitor disease progression. Contemporary guidelines from the American Academy of Neurology and other bodies continue to support the use of cholinesterase inhibitors like donepezil in managing mild to moderate AD. Research continues to explore novel disease-modifying therapies targeting amyloid and tau pathology, though symptomatic management remains the current standard of care.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "a female patient who report throat discomfort and a \u201cclicking tinnitus\u201d subside during her sleep, on exam there is an objective clicking sound and other wise her exam is normal what is the diagnosis:",
    "option_a": "palatal tremor",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Palatal tremor (or palatal myoclonus) is characterized by rhythmic contractions of the soft palate muscles. This condition is often clinically evident through an audible clicking sound, which can sometimes be heard by the patient and observed on examination. Palatal tremor may be classified as either essential or symptomatic. Essential palatal tremor occurs in the absence of structural brain lesions and is thought to be due to intrinsic abnormalities within the central nervous system pathways controlling palatal movement. The clicking tinnitus is produced when the repetitive contractions cause the soft palate to intermittently contact adjacent structures, a process that typically ceases during sleep. Patients often report throat discomfort and an audible 'clicking' sound that is intermittent and typically disappears during sleep. The objective clicking sound on examination confirms the diagnosis. This condition is benign and distinct from other causes of tinnitus or abnormal orofacial movements. Diagnosis is largely clinical, based on history and physical examination. Differential diagnoses include middle ear myoclonus, focal dystonia, or other forms of orofacial myoclonus. Neuroimaging such as MRI may be used when a symptomatic cause (e.g., a lesion in the Guillain-Mollaret triangle) is suspected, but in essential palatal tremor, imaging is usually normal. Management is usually conservative in essential palatal tremor as the condition is benign. If symptoms are bothersome, botulinum toxin injections into the palatal muscles can be considered as a second-line treatment to reduce the tremor. For women who are pregnant or lactating, the risks and benefits of botulinum toxin must be carefully weighed, and conservative management is typically favored due to limited safety data in these populations. Option A (Palatal tremor) is correct as the clinical presentation of throat discomfort and clicking tinnitus that subsides during sleep fits the description of palatal myoclonus. The absence of abnormalities on general examination further supports this diagnosis. Other options (if provided) would likely represent alternative causes that do not match the specific constellation of findings. 1. Palatal tremor produces an audible clicking sound that is often absent during sleep. 2. It is generally a benign condition and may not require extensive intervention if asymptomatic. 3. Botulinum toxin injections are an option for symptomatic relief but require careful consideration regarding side effects, especially in special populations. Recent studies confirm that essential palatal tremor is best managed conservatively, with botulinum toxin reserved for particularly distressing cases. Ongoing research is focused on better understanding the neural circuitry involved in palatal myoclonus, potentially leading to more targeted therapies in the future.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Pet scan in LBD:",
    "option_a": "Occipital",
    "option_b": "Temporoparietal",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Lewy Body Dementia (LBD), also known as Dementia with Lewy bodies (DLB), is a neurodegenerative disorder characterized by cognitive fluctuations, visual hallucinations, and parkinsonism. Neuroimaging, including PET scans, plays a crucial role in differentiating LBD from other dementias by identifying distinct patterns of brain metabolism. LBD is associated with the accumulation of alpha\u2010synuclein inclusions known as Lewy bodies. This pathology primarily affects subcortical and cortical regions, with a notable reduction in occipital metabolism. The presence of occipital hypometabolism correlates with visual processing deficits and hallucinations seen in LBD. Patients with LBD often present with visual hallucinations and cognitive fluctuations, which are linked to the characteristic occipital hypometabolism observed on FDG-PET scans. This contrasts with Alzheimer\u2019s disease, which more typically exhibits temporoparietal hypometabolism. Differentiation of LBD from Alzheimer\u2019s disease and other dementias is critical. FDG-PET imaging is used to identify regional metabolic patterns: occipital hypometabolism is highly suggestive of LBD, whereas temporoparietal hypometabolism is more common in Alzheimer\u2019s disease. Other differentials include frontotemporal dementia (frontal lobe hypometabolism) and vascular dementia (patchy hypometabolic areas corresponding to vascular territories). Management of LBD includes symptomatic treatment with cholinesterase inhibitors (e.g., rivastigmine, donepezil) as first-line therapy to help improve cognitive symptoms. Caution with antipsychotics is warranted due to severe sensitivity reactions. Second-line treatments might include memantine for additional cognitive support. Although LBD typically affects older adults, if encountered in a younger woman of childbearing potential (rare), the potential teratogenicity or risk during lactation must be weighed, often favoring non-pharmacological management whenever possible. Option A (Occipital) is correct because FDG-PET imaging in LBD typically reveals occipital hypometabolism. Option B (Temporoparietal) is more consistent with Alzheimer\u2019s disease and does not represent the typical metabolic pattern seen in LBD. The other options, not provided here, would presumably be less consistent with the imaging findings specific to LBD. 1. Occipital hypometabolism on FDG-PET is a key imaging marker to distinguish LBD from other dementias. 2. LBD is associated with significant visual hallucinations and cognitive fluctuations. 3. Caution is necessary with antipsychotic use in LBD due to increased sensitivity. Recent guidelines and studies reinforce the diagnostic utility of FDG-PET in LBD, highlighting occipital hypometabolism as a differentiating feature. Ongoing research continues to explore targeted treatments for LBD, with a focus on optimizing cholinesterase inhibitor use and minimizing neuroleptic exposure.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Case of an elderly patient and symptoms suggestive of MSA:\n-most common presenting symptoms is impairment of down gaze\n-Autonomic insufficiency is characteristic of autonomic type of This condition\n-the cognitive impairment of amnestic type\n-the pt may have pyramidal sign",
    "option_a": "states that impaired down gaze is the most common presenting symptom in MSA, which is incorrect since vertical gaze palsy is classically seen in PSP. Option B, which highlights autonomic insufficiency, is the most characteristic and therefore correct. Option C (amnestic type cognitive impairment) does not correspond with typical MSA features, and while Option D (possible pyramidal signs) may sometimes be seen, it is less characteristic than the autonomic dysfunction described in Option B.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of parkinsonian features, cerebellar dysfunction, and marked autonomic impairment. Importantly, ocular motor abnormalities such as impaired down gaze are typical for Progressive Supranuclear Palsy (PSP), not MSA. In MSA, autonomic failure (eg, orthostatic hypotension, urinary incontinence) is a key clinical feature. MSA is associated with accumulation of alpha\u2011synuclein in glial cytoplasmic inclusions leading to degeneration in the striatonigral and olivopontocerebellar systems. Degeneration in central autonomic networks (including brainstem and spinal cord regions) explains the prominent autonomic dysfunction. In contrast, vertical gaze palsy is linked with midbrain involvement, as seen in PSP. Clinically, patients with MSA present with parkinsonian signs that are poorly responsive to levodopa, cerebellar signs (in MSA\u2010C subtype), and prominent autonomic failure. Although pyramidal signs can be observed in a subset of patients, impaired down gaze is not typical and should prompt consideration of alternative diagnoses such as PSP. Additionally, significant amnestic-type cognitive impairment is uncommon in MSA. The differential diagnosis includes Parkinson\u2019s disease, PSP, and corticobasal degeneration. Differentiation hinges on clinical clues: PSP features vertical gaze palsy (particularly impaired down gaze), whereas MSA is hallmarked by autonomic failure and a mixed picture of parkinsonism and cerebellar dysfunction. Neuroimaging, though not definitive, can support the diagnosis by highlighting atrophy patterns, and autonomic testing is useful in assessing dysautonomia. There is no cure for MSA. First-line management is supportive and symptomatic. Parkinsonian features may be trialed with levodopa, though response is usually limited. Autonomic dysfunction is managed with non-pharmacological interventions (eg, increased fluid and salt intake) and medications like midodrine or fludrocortisone. In pregnancy and lactation, these agents must be used with caution (most are Category C), and risks versus benefits should be carefully weighed with multidisciplinary input. Rehabilitation, physical therapy, and symptomatic management for cerebellar signs are also important. Option A states that impaired down gaze is the most common presenting symptom in MSA, which is incorrect since vertical gaze palsy is classically seen in PSP. Option B, which highlights autonomic insufficiency, is the most characteristic and therefore correct. Option C (amnestic type cognitive impairment) does not correspond with typical MSA features, and while Option D (possible pyramidal signs) may sometimes be seen, it is less characteristic than the autonomic dysfunction described in Option B. \u2022 Autonomic failure (eg, orthostatic hypotension, urinary incontinence) is a key clinical feature of MSA.  \u2022 Impaired down gaze is more characteristic of PSP than MSA.  \u2022 A limited response to levodopa supports the diagnosis of MSA over Parkinson\u2019s disease. Recent diagnostic criteria for MSA emphasize the centrality of autonomic dysfunction in the diagnosis, with imaging and biomarkers being actively researched to improve early diagnostic accuracy. Studies continue to refine the role of neuroimaging in differentiating MSA from other parkinsonian syndromes.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Vague Scenario about LBD ASKING ABOUT DIAGNOSIS",
    "option_a": "",
    "option_b": "represents the diagnosis of Lewy Body Dementia (or Dementia with Lewy Bodies), it is correct since the key features such as fluctuating cognition, visual hallucinations, and parkinsonism align with LBD. Other options likely represent alternative dementias (such as Alzheimer\u2019s or frontotemporal dementia) which do not typically present with the combination of features seen in LBD.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Lewy Body Dementia (LBD), also known as Dementia with Lewy Bodies (DLB), is a neurodegenerative disorder presenting with a distinctive clinical triad: fluctuating cognition, prominent visual hallucinations, and parkinsonian motor features. It is a major cause of dementia in older adults. The condition is characterized by the deposition of alpha\u2011synuclein in neuronal cytoplasm, forming Lewy bodies predominantly in cortical regions. This pathology disrupts neuronal function and connectivity, leading to the neuropsychiatric and motor symptoms typically seen in LBD. There is also pathophysiologic overlap with Parkinson\u2019s disease. Patients with LBD often exhibit marked fluctuations in attention and alertness, early visual hallucinations, and parkinsonism that may appear before or after the onset of cognitive impairment. These features help differentiate LBD from Alzheimer\u2019s disease, which primarily presents with memory deficits, and from Parkinson\u2019s disease dementia, which features a later onset of cognitive decline. The diagnosis of LBD is based on clinical criteria (eg, the McKeith criteria) supported by imaging (such as reduced dopamine transporter uptake on SPECT/PET scans) and the characteristic symptom profile. Differential diagnoses include Alzheimer\u2019s disease, vascular dementia, and frontotemporal dementia, each with distinct presenting features and progression patterns. First-line treatment includes cholinesterase inhibitors (eg, rivastigmine or donepezil) which have been shown to improve cognitive symptoms and reduce hallucinations. For motor features, a cautious trial of levodopa can be considered. Antipsychotics should be used with extreme caution due to the risk of severe neuroleptic sensitivity. Although dementia in pregnancy is rare, if encountered, treatment decisions must balance maternal benefits with fetal risks, typically favoring non-pharmacologic supportive management. Lactating mothers should similarly be managed conservatively with careful assessment of medication safety profiles. Assuming that Option B represents the diagnosis of Lewy Body Dementia (or Dementia with Lewy Bodies), it is correct since the key features such as fluctuating cognition, visual hallucinations, and parkinsonism align with LBD. Other options likely represent alternative dementias (such as Alzheimer\u2019s or frontotemporal dementia) which do not typically present with the combination of features seen in LBD. \u2022 Fluctuating cognition and early visual hallucinations are hallmark features of LBD.  \u2022 Patients with LBD are often highly sensitive to typical antipsychotics.  \u2022 Differentiating LBD from Alzheimer\u2019s and Parkinson\u2019s disease dementia is crucial for proper management. Recent research and updated consensus criteria (McKeith criteria) have reinforced the significance of REM sleep behavior disorder and visual hallucinations as clinical clues for LBD. Advances in neuroimaging (such as DAT scans) continue to improve diagnostic accuracy and guide management.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Patient developed cognitive impairment and ataxia MRI showed mamillary body high signals?",
    "option_a": "Thiamine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Wernicke\u2019s encephalopathy is an acute neuropsychiatric condition caused by thiamine (vitamin B1) deficiency. It typically presents with a classical triad of confusion, ataxia, and ocular abnormalities, though the full triad is not always present. High\u2010signal intensity in the mamillary bodies on MRI is a radiological hallmark of this condition. Thiamine is a critical cofactor in cerebral energy metabolism. Its deficiency leads to impaired metabolism in brain regions with high metabolic demands such as the mamillary bodies, thalamus, and periaqueductal gray matter. The resulting neuronal injury, edema, and potential hemorrhage are responsible for the clinical presentation and MRI findings. Patients often present with cognitive impairment (altered mental status), ataxia, and sometimes ocular abnormalities (nystagmus or ophthalmoplegia). The presence of mamillary body hyperintensities on MRI supports the diagnosis of Wernicke\u2019s encephalopathy, prompting urgent treatment. It is most commonly seen in chronic alcohol users and malnourished individuals but can be seen in any state of severe nutritional deficiency. Diagnosis is primarily clinical, supported by characteristic MRI findings. Differential diagnoses include cerebellar stroke, other metabolic encephalopathies, and posterior circulation events. However, the combination of acute cognitive changes, ataxia, and mamillary body signal changes strongly favors Wernicke\u2019s encephalopathy. Immediate treatment with high-dose intravenous thiamine is the cornerstone of management. Guidelines typically recommend an IV thiamine dose of 500 mg three times daily for 2\u20133 days, followed by lower doses. It is critical to administer thiamine before any glucose-containing fluids to prevent exacerbation of the condition. Thiamine supplementation is safe in pregnancy and lactation, making it the ideal treatment in these populations when deficiency is suspected. Option A, which recommends thiamine supplementation, is correct given the clinical and radiological findings indicative of Wernicke\u2019s encephalopathy. Other options (not specified here) would not address the underlying thiamine deficiency and could delay critical treatment. \u2022 Always administer thiamine before glucose in patients at risk for deficiency to prevent precipitating or worsening Wernicke\u2019s encephalopathy.  \u2022 Mamillary body hyperintensities on MRI are a key diagnostic clue.  \u2022 Early treatment is essential to prevent progression to irreversible Korsakoff syndrome. Contemporary guidelines emphasize the need for prompt, high-dose thiamine administration in suspected cases. Recent studies have reinforced MRI as a useful tool in identifying characteristic changes, and ongoing research continues to explore optimal dosing strategies to prevent long-term cognitive deficits.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pathology showed Lewi body, what Dx:",
    "option_a": "Lewi body dementia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Lewy body pathology is characterized by the abnormal accumulation of alpha\u2011synuclein within neurons. When this pathology is extensive, particularly in cortical areas, it is associated with Dementia with Lewy Bodies (DLB), a condition marked by cognitive decline, parkinsonism, and neuropsychiatric symptoms. Lewy bodies are intracytoplasmic eosinophilic inclusions composed predominantly of alpha\u2011synuclein. In DLB, the deposition occurs not only in the brainstem (as seen in Parkinson\u2019s disease) but also in cortical regions, which is correlated with the cognitive impairments and visual hallucinations observed clinically. Patients with DLB typically present with a combination of dementia, parkinsonian motor symptoms, fluctuations in cognition, and vivid visual hallucinations. The diagnosis is supported by pathological findings of widespread Lewy bodies. Although Lewy bodies can be found in Parkinson\u2019s disease, in DLB they are more prominent in cortical regions, which accounts for the early cognitive deficits. Diagnosis is made on a clinical basis using criteria such as the McKeith criteria, and can be supported by neuroimaging and, ultimately, autopsy findings showing cortical Lewy bodies. Differential diagnoses include Parkinson\u2019s disease dementia (where cognitive decline occurs later), Alzheimer\u2019s disease, and vascular dementia. A clear history and pattern of symptom progression help differentiate these conditions. Management of DLB is symptomatic. Cholinesterase inhibitors (eg, rivastigmine) are first-line for cognitive and neuropsychiatric symptoms. Parkinsonian motor symptoms may be managed with low-dose levodopa, though patients often show limited response. Use of antipsychotic medications requires extreme caution due to potential severe neuroleptic sensitivity. Although DLB is rare during pregnancy, management in such instances would necessitate a careful balancing of maternal and fetal risks with a preference for supportive and non-pharmacologic interventions in both pregnancy and lactation. Option A, 'Lewy body dementia', is correct when pathology shows the presence of Lewy bodies in the relevant distribution (ie, including cortical areas) in a patient with cognitive decline. Alternative options may refer to conditions like Parkinson\u2019s disease, but without clarification of clinical features, and given the context, the marked answer is appropriate. \u2022 Lewy bodies, when present in cortical regions, are strongly associated with DLB.  \u2022 Patients with DLB can be highly sensitive to neuroleptics\u2014use these medications with caution.  \u2022 Differentiation from Parkinson\u2019s disease is based on the early onset of cognitive impairment in DLB. Recent research has refined the diagnostic criteria for DLB, emphasizing the importance of early cognitive impairment and visual hallucinations alongside parkinsonian features. Advances in neuroimaging and biomarker studies are increasingly aiding in the early and accurate diagnosis of DLB.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Same scenario ask about the conversion rate of cognitive to dementia?",
    "option_a": "6% - 10%",
    "option_b": "10 - 15%",
    "option_c": "21 - 30%",
    "option_d": "31 - 90%",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Mild Cognitive Impairment (MCI) is an intermediate state between the expected cognitive decline of normal aging and more serious decline of dementia. One key aspect of MCI is its conversion rate to a dementia syndrome, typically Alzheimer\u2019s dementia, with a generally quoted annual conversion rate. Underlying MCI, particularly the amnestic subtype, is the early accumulation of Alzheimer\u2019s pathology (amyloid plaques, tau protein tangles) leading to synaptic dysfunction and neuronal death. Studies tracking cohorts over time have shown that approximately 10-15% of individuals with MCI can progress to dementia each year. However, rates can vary depending on factors such as the type of MCI, comorbidities, and biomarkers. Patients with MCI present with subtle deficits in memory or other cognitive domains, which do not yet interfere significantly with daily functioning. The estimated 10-15% conversion rate per year underscores the need for regular re-evaluation, as early dementia is characterized by more pronounced memory impairment and functional decline. Diagnosis of MCI is made using clinical cognitive tests (e.g., MoCA, MMSE) and neuropsychological evaluation. Differential diagnoses include normal aging, depression (pseudodementia), and early dementia. Biomarker studies and neuroimaging (MRI, PET) can help differentiate MCI due to Alzheimer\u2019s disease from other causes. Management of MCI is primarily focused on regular monitoring, lifestyle modifications, cognitive training, and vascular risk factor control. There are no FDA-approved pharmacologic treatments specifically for MCI. For patients who are pregnant or lactating, non-pharmacologic management is emphasized to avoid unnecessary drug exposure. Option A (6%-10%) underestimates the conversion rate, while Options C (21%-30%) and D (31%-90%) overestimate it; Option B (10%-15%) is well supported by the literature for the annual conversion rate from MCI to dementia. 1. MCI is a high-risk state for dementia with an estimated 10-15% annual conversion rate. 2. Early detection and regular follow-up are key. 3. Non-pharmacologic interventions remain the cornerstone of management. Recent longitudinal studies and meta-analyses continue to support an annual conversion rate of 10-15% in MCI patients, and research is ongoing to identify biomarkers that can refine risk prediction. Current clinical guidelines emphasize the importance of monitoring and risk factor modification over pharmacotherapy in MCI.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of MCI ask about treatment?",
    "option_a": "Rivastagmine",
    "option_b": "High dose vit E",
    "option_c": "Regular follow up",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Dementia",
    "explanation": "Mild Cognitive Impairment (MCI) represents a state where cognitive changes are noticeable but not severe enough to interfere with activities of daily living. The primary management approach is observation rather than aggressive pharmacologic intervention. MCI involves subtle neurodegenerative changes, often related to early Alzheimer\u2019s pathology, though not advancing to the extent of causing dementia. The pathologic burden may include amyloid deposition and tau pathology, but neuronal loss is less pronounced compared to dementia. Patients with MCI may have reported memory lapses or mild cognitive deficits on testing; however, daily functioning is largely maintained. Because the progression to dementia is variable, regular follow-up is essential to monitor any decline. The diagnosis of MCI is made through clinical history, cognitive testing (MMSE, MoCA), and sometimes neuropsychological evaluation. Differential diagnoses include depression-related cognitive changes and normal aging. Neuroimaging can also be used to exclude other pathologies. There is no established pharmacological treatment for MCI. The current guidelines recommend regular clinical follow-up and lifestyle interventions (e.g., cognitive training, exercise, diet) to potentially delay progression. In pregnancy and lactation, non-pharmacologic management is even more emphasized. Option A (Rivastigmine) is a cholinesterase inhibitor approved for Alzheimer\u2019s dementia but not for MCI. Option B (High dose vitamin E) is not recommended due to lack of consistent evidence and possible risks. Option C (Regular follow up) is the appropriate answer to monitor for progression and manage risk factors. 1. MCI management centers on observation and lifestyle modifications rather than active pharmacotherapy. 2. Regular cognitive evaluations are critical to detect any progression. 3. Emphasize management of vascular risk factors. Recent guidelines and studies have failed to demonstrate a consistent benefit of cholinesterase inhibitors or vitamin E in MCI, reinforcing the importance of regular follow-up and non-pharmacologic interventions.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario about DLB (continuum). Dx? Dementia, cognitive fluctuation, visual hallucinations, REM sleep disorder, parkinsonism",
    "option_a": "DLB",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Dementia with Lewy Bodies (DLB) is a neurodegenerative disorder characterized by a unique combination of cognitive impairment, visual hallucinations, fluctuating attention, REM sleep behavior disorder, and parkinsonism. This clinical picture differentiates it from other forms of dementia. DLB is associated with the abnormal accumulation of alpha-synuclein protein (Lewy bodies) in the cortical and subcortical regions. This accumulation disrupts neural transmission affecting cognition, perception, and motor function. The presence of Lewy bodies in the brainstem also underlies the parkinsonism seen in these patients. The symptom complex \u2013 cognitive fluctuations, recurrent visual hallucinations, REM sleep behavior disorder, and parkinsonism \u2013 is strongly indicative of DLB. These manifestations correlate with the distribution of Lewy bodies in various brain regions, helping differentiate it from Alzheimer\u2019s disease or Parkinson\u2019s disease dementia. Diagnosis is clinical, based on core features. Differential diagnoses include Parkinson\u2019s disease dementia (timing of motor vs cognitive symptoms), Alzheimer\u2019s disease (with less prominent hallucinations and fluctuations), and vascular dementia. Imaging and biomarkers (DAT scans) can supplement the clinical evaluation. Management of DLB includes using cholinesterase inhibitors to improve cognitive and neuropsychiatric symptoms and cautious use of atypical antipsychotics if needed. In pregnancy or lactation, the use of these drugs is generally avoided, and supportive care is emphasized. Option A directly identifies the condition as Dementia with Lewy Bodies (DLB), which is correct given the described constellation of symptoms. Other options are not provided, reinforcing that A is the correct diagnosis. 1. Fluctuating cognition and visual hallucinations are hallmark features of DLB. 2. REM sleep behavior disorder is commonly associated with DLB. 3. Differentiation from Parkinson\u2019s disease dementia is based on the timing of motor versus cognitive symptom onset. Recent updates in DLB diagnostic criteria emphasize the importance of supportive biomarkers (e.g., DAT imaging) and clinical features for early diagnosis. Current research is focused on early detection and management strategies to improve quality of life.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario DLB, patient developed hallucination and psychiatric. Treatment:",
    "option_a": "Quatiapine",
    "option_b": "Rivastagmine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "DLB patients frequently exhibit neuropsychiatric symptoms including visual hallucinations and behavioral changes. However, the management of these symptoms needs to be approached with caution due to the patients\u2019 sensitivity to antipsychotic medications. In DLB, there is a marked cholinergic deficit due to the loss of cholinergic neurons as well as the presence of Lewy bodies. This deficit is linked not only to cognitive impairment but also to neuropsychiatric symptoms such as hallucinations. Dopaminergic dysfunction contributes to parkinsonism. The use of antipsychotics can further worsen motor symptoms by antagonizing dopamine receptors. Patients with DLB often develop visual hallucinations and delusional thinking that can be distressing. These symptoms are typically intertwined with fluctuating cognition and parkinsonism, making treatment challenging due to the risk of severe neuroleptic sensitivity. The diagnosis of DLB is primarily clinical, supported by core features (fluctuating cognition, visual hallucinations, REM sleep behavior disorder, parkinsonism) and biomarkers (such as DAT scans). Differentials include Alzheimer\u2019s disease (which has less prominent hallucinations) and Parkinson\u2019s disease dementia (where motor symptoms precede cognitive impairment). First-line management for neuropsychiatric symptoms in DLB involves optimizing cholinesterase inhibitors, such as rivastigmine, which have been shown to improve both cognitive and visual hallucination symptoms. In patients who continue to exhibit severe psychiatric symptoms, careful and low-dose use of atypical antipsychotics (e.g., quetiapine) may be considered, but only after ruling out benefits from cholinesterase inhibitors. Special caution is warranted due to the high risk of worsening parkinsonism and inducing severe adverse effects. For pregnant or lactating women, non-pharmacologic interventions and the cautious use of medications with the best safety profile are emphasized, although DLB is very uncommon in this demographic. Option A (Quetiapine) is a second-generation antipsychotic sometimes used in refractory cases; however, it is not considered first-line because patients with DLB are extremely sensitive to neuroleptics, and antipsychotics can exacerbate motor symptoms. Option B (Rivastagmine) is a cholinesterase inhibitor that is widely recommended as first-line therapy in DLB to help control hallucinations and cognitive fluctuations, making it the correct choice. 1. Cholinesterase inhibitors are the cornerstone of treating neuropsychiatric symptoms in DLB. 2. DLB patients have a high risk of severe sensitivity to antipsychotics, so these should be used only as a last resort. 3. Always aim to optimize non-pharmacological and cognitive-based therapies before adding psychotropic medications. Recent guidelines from dementia societies and expert consensus strongly favor the use of cholinesterase inhibitors (e.g., rivastagmine) in DLB over antipsychotics. Emerging research also focuses on minimizing antipsychotic exposure in these patients due to associated morbidity and mortality. Studies continue to validate rivastagmine\u2019s efficacy in reducing hallucinations and improving overall cognitive function in DLB.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "80 years old came with concerns of his memory function as he is forgetting names of the people and forgetting where he is putting his stuff; he is totally independent. What is the diagnosis?",
    "option_a": "Alzehimer disease.",
    "option_b": "Normal Aging",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Normal aging is characterized by mild cognitive changes that are expected as part of the aging process. Typically, these changes include occasional lapses in memory (such as misplacing items or having momentary difficulty recalling names) but without significant interference in daily activities or independence. Normal aging involves gradual neuronal loss, slower synaptic processing, and mild changes in brain volume. Unlike Alzheimer\u2019s disease, there is no widespread pathological accumulation of amyloid plaques or neurofibrillary tangles. The changes are subtle, and compensatory neural mechanisms help maintain function. An 80\u2010year\u2010old who occasionally forgets names or misplaces objects yet remains fully independent in daily living is more consistent with age\u2010related memory changes. In contrast, Alzheimer\u2019s disease would typically demonstrate progressive cognitive decline with interference in social or occupational functioning. The evaluation involves a clinical assessment of cognitive functions (often using screening tools such as the MMSE or MoCA), assessment of activities of daily living, and history to differentiate normal aging from mild cognitive impairment or dementia. Differential diagnoses include Alzheimer\u2019s disease, vascular cognitive impairment, and other causes of dementia. Management is largely centered on reassurance, lifestyle modification (regular physical exercise, cognitive stimulation, healthy diet), and addressing cardiovascular risk factors. There is no pharmacologic treatment for normal aging. In elderly patients (including those who may be pregnant or lactating, although such a situation is extremely rare), the focus is on supportive care and risk reduction. Option A (Alzheimer disease) implies a progressive dementia with impairment in function, which does not match the patient\u2019s preserved independence. Option B (Normal Aging) is correct as the mild complaints described are typical for normal age\u2010related cognitive changes. 1. Memory lapses in the elderly do not necessarily imply dementia if daily functioning remains intact. 2. It is important to differentiate between normal aging and the early stages of neurodegenerative disorders by evaluating the impact on everyday activities. Recent research emphasizes the importance of distinguishing normal cognitive aging from pathological decline using functional assessments and biomarkers. Guidelines recommend lifestyle modification and cognitive engagement as preventive strategies against further decline.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with behavioral changes, what is the gene defect:",
    "option_a": "TDP-43",
    "option_b": "",
    "option_c": "",
    "option_d": "), assumed to represent a specific genetic mutation (likely the GRN mutation) linked to TDP",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal dementia (FTD), particularly the behavioral variant, is often linked to genetic mutations. Genetic defects in FTD affect proteins that are critical in normal neuronal function. Although several genes have been implicated, common ones include mutations in the GRN (progranulin), MAPT (microtubule\u2010associated protein tau), and C9orf72 genes. Mutations such as those in the GRN gene lead to a reduction in progranulin levels, resulting in abnormal protein handling and the accumulation of TDP-43 (a 43-kDa transactive response DNA-binding protein) inclusions. This abnormal deposition promotes neurodegeneration in the frontal and temporal lobes, manifesting as behavioral changes. Patients with FTD often present with marked behavioral changes including disinhibition, apathy, loss of empathy, and compulsive behaviors. The underlying pathology correlates with the regions responsible for behavior and personality. Although option A lists TDP-43, it refers to a pathological protein rather than a gene defect. The diagnostic workup for FTD involves detailed history-taking, neuropsychological testing, and neuroimaging (MRI, PET). It is essential to differentiate FTD from Alzheimer\u2019s disease (which primarily affects memory) and primary psychiatric disorders. Genetic testing may be indicated in patients with a family history. There is no curative treatment for FTD. Management focuses on symptomatic treatment using behavioral interventions, SSRIs to manage disinhibition or compulsivity, and support for caregivers. In cases of familial FTD, genetic counseling is recommended. Although FTD is most common in mid to late adulthood, considerations during pregnancy and lactation are generally not applicable but if encountered, non-pharmacological strategies and careful use of medications with safety profiles in pregnancy would be essential. Option A states \u2018TDP-43\u2019 which describes a protein aggregate rather than a gene defect, making it an imprecise answer to the question. The marked answer (Option D), assumed to represent a specific genetic mutation (likely the GRN mutation) linked to TDP-43 pathology, is therefore correct. 1. A GRN mutation is one of the genetic defects seen in the behavioral variant of FTD and is associated with TDP-43 protein inclusions. 2. It's important to distinguish genetic causes from protein pathologies; TDP-43 is the protein, while GRN represents the gene defect causing its accumulation. The latest research and consensus guidelines emphasize genetic testing in familial FTD cases. Novel therapeutic targets are being explored, and current management remains focused on symptomatic and supportive care.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Typical hx of LBD, PET showed posterior CC abnormality (the pic is not obvious), what is Dx?",
    "option_a": "LBD (clear from the Hx).",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Dementia with Lewy Bodies (DLB) is a neurodegenerative disorder that presents with a combination of cognitive decline, visual hallucinations, Parkinsonian features, and fluctuations in attention and alertness. Clinical history plays a pivotal role in the diagnosis. Lewy Body Dementia is characterized by the accumulation of alpha-synuclein protein within neurons in cortical and subcortical regions. A notable imaging marker is the \u2018cingulate island sign\u2019\u2014relative preservation of the posterior cingulate metabolism compared to the precuneus and cuneus\u2014which helps differentiate DLB from Alzheimer\u2019s disease, where the posterior cingulate typically shows decreased metabolism. A typical clinical history of fluctuating cognition, visual hallucinations, and Parkinsonian symptoms strongly points toward DLB. Neuroimaging such as PET can assist in confirming the pattern of metabolic changes, although images may at times be subtle. The diagnosis of DLB is based on clinical criteria supported by imaging. Differential diagnoses include Alzheimer\u2019s disease (characterized by more pronounced memory loss and different PET patterns) and vascular dementia. The presence of the cingulate island sign on PET imaging particularly supports DLB. Management involves cholinesterase inhibitors (e.g., rivastigmine) as first-line therapy for cognitive symptoms; caution is required with antipsychotics due to sensitivity and potential worsening of motor symptoms. Non-pharmacological interventions and supportive care are also essential. Although DLB predominantly affects older adults (pregnancy and lactation issues are not applicable), when managing any dementia in women of childbearing age, medications with known safety profiles during pregnancy and lactation should be chosen. Option A states \u2018LBD (clear from the Hx)\u2019 which fits well with a clinical history suggestive of Lewy Body Dementia and is supported by PET imaging findings (even if the imaging finding is a subtle abnormality in the posterior cingulate that may be interpreted as part of the cingulate island sign). Thus, option A is the correct choice. 1. The \u2018cingulate island sign\u2019 on PET imaging is a useful biomarker to help distinguish DLB from Alzheimer\u2019s disease. 2. Clinical diagnosis of DLB relies heavily on the presence of visual hallucinations, cognitive fluctuations, and motor features. Recent consensus guidelines stress the importance of integrating clinical criteria with advanced imaging techniques in the diagnosis of DLB. Ongoing research is also exploring potential disease-modifying therapies for alpha-synucleinopathies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with broca\u2019s aphasia. What is the localization:",
    "option_a": "frontoprietal operculum",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Broca\u2019s aphasia is a type of non-fluent aphasia caused by injury to the language-dominant hemisphere, typically involving areas responsible for language production. It is most classically associated with lesions in Broca\u2019s area, located in the inferior frontal gyrus. Lesions in Broca\u2019s area (Brodmann areas 44 and 45) disrupt the neural networks involved in language production. The damage leads to impaired speech fluency and effortful, halting articulation while relatively sparing comprehension. Patients with Broca\u2019s aphasia present with non-fluent, telegraphic speech. They often struggle with word retrieval and constructing grammatically complex sentences, although their understanding of language is largely preserved. The defect is typically localized to the dominant frontal lobe. Diagnosis relies on clinical language assessments, detailed history, and neuroimaging (typically MRI) to localize the lesion. Differential diagnoses include other aphasic syndromes such as transcortical motor aphasia or global aphasia, which differ in fluency and comprehension profiles. First-line management involves early and aggressive speech and language therapy to maximize recovery. In cases secondary to stroke, acute management of stroke and secondary prevention are crucial. For pregnant or lactating patients (though rare in this context), non-pharmacological rehabilitation remains the mainstay while ensuring medications used in acute stroke management are safe. Option A, which localizes the deficit to the frontoprietal operculum (interpreted as the frontal operculum region including Broca\u2019s area), is correct. Other options (if provided) that suggest alternative localizations (such as the temporal lobe or parietal cortex) would be inconsistent with the classical presentation of Broca\u2019s aphasia. 1. Broca\u2019s area is typically situated in the dominant hemisphere\u2019s inferior frontal gyrus (pars opercularis and pars triangularis). 2. Despite non-fluent, effortful speech, comprehension in Broca\u2019s aphasia is often relatively preserved. Recent studies underscore the benefits of early, intensive speech therapy on neuroplasticity and recovery in post-stroke aphasia. Advances in neuroimaging continue to refine lesion localization, which in turn informs rehabilitation strategies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Young Alzheimer, what is the gene defect?",
    "option_a": "APP",
    "option_b": "ApoE",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Early-onset familial Alzheimer\u2019s disease is a genetically mediated form of Alzheimer\u2019s that generally presents before the age of 65. Key genes implicated include the amyloid precursor protein (APP) gene along with presenilin-1 (PSEN1) and presenilin-2 (PSEN2). In the context of the provided options, the APP gene mutation is a well\u2010established defect leading to abnormal amyloid processing. Mutations in the APP gene result in an altered processing of amyloid precursor protein. This abnormal cleavage increases the production of beta-amyloid peptides, which aggregate into plaques. These plaques trigger a cascade of neuroinflammation and neuronal loss, hallmarks of Alzheimer\u2019s pathology. Although PSEN1 mutations are the most common in early\u2010onset cases, APP mutations remain a valid and recognized cause. Patients with early-onset Alzheimer\u2019s typically present with memory impairment, executive dysfunction, and other cognitive deficits at a younger age than those with sporadic or late-onset Alzheimer\u2019s. The familial history and rapid progression in some families reinforce the role of these genetic mutations. Diagnosis is based on clinical history, neuropsychological testing, and, when indicated, genetic testing. Differential diagnoses include other causes of early cognitive decline such as frontotemporal dementia or vascular cognitive impairment. Genetic confirmation via sequencing can help differentiate among familial Alzheimer\u2019s mutations. There is no cure for Alzheimer\u2019s disease, but management includes symptomatic treatments such as cholinesterase inhibitors and NMDA receptor antagonists. In genetic forms, counseling and family planning are important. During pregnancy or lactation, treatment plans must be modified carefully; cholinesterase inhibitors are typically avoided unless the potential benefits outweigh the risks, and supportive measures become even more pivotal. Option A (APP) is correct because mutations in the APP gene are a known cause of early-onset familial Alzheimer\u2019s. Option B (ApoE) refers to a risk factor associated with late-onset Alzheimer\u2019s rather than a direct gene defect in young patients. 1. Remember that familial Alzheimer\u2019s disease often involves autosomal dominant mutations with an earlier age of onset. 2. APP mutations account for a subset of cases even though PSEN1 mutations are more common overall. 3. Genetic counseling is crucial for families with early-onset Alzheimer\u2019s. Recent research continues to refine our understanding of amyloid processing and its genetic underpinnings in Alzheimer\u2019s disease. While gene therapy is still investigational, advanced genetic sequencing helps in early diagnosis and risk stratification in affected families.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Same patient; what you will give him for treatment?",
    "option_a": "rivastigmine",
    "option_b": "lifestyle modification",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "The cornerstone of Alzheimer\u2019s treatment involves symptomatic management using cholinesterase inhibitors. These agents aim to boost cholinergic transmission to alleviate some cognitive deficits. Alzheimer\u2019s disease is characterized by a deficiency in acetylcholine due to neuronal loss in cholinergic pathways. Cholinesterase inhibitors, such as rivastigmine, work by inhibiting the enzyme that breaks down acetylcholine, thereby increasing its availability at synapses and potentially improving cognitive function. Patients with Alzheimer\u2019s often present with memory loss, confusion, and language difficulties. Early intervention with cholinesterase inhibitors can provide modest symptomatic improvement, especially in mild to moderate stages of the disease. The diagnosis of Alzheimer\u2019s disease is clinical, supported by neuroimaging and neuropsychological testing. Differential diagnoses include vascular dementia, Lewy body dementia, and frontotemporal dementia. The response to cholinesterase inhibitors can provide additional supportive evidence. First-line management for mild to moderate Alzheimer\u2019s involves cholinesterase inhibitors like rivastigmine, donepezil, or galantamine. In moderate to severe stages, memantine, an NMDA receptor antagonist, may be added. In pregnant or lactating women, the use of cholinesterase inhibitors requires careful risk-benefit analysis since their safety profile in these populations is not well established, and non-pharmacological management is preferred if possible. Option A (rivastigmine) is correct as it is an approved treatment for Alzheimer\u2019s disease. Option B (lifestyle modification) is beneficial as an adjunct for overall health improvement but is not considered a primary treatment for symptoms in Alzheimer\u2019s disease. 1. Cholinesterase inhibitors provide modest symptomatic benefit in Alzheimer\u2019s disease. 2. Early treatment may slow progression of symptomatic decline. 3. Always consider the patient\u2019s overall health status when evaluating pharmacologic versus non-pharmacologic interventions. The latest guidelines continue to support the use of cholinesterase inhibitors in early Alzheimer\u2019s disease, with ongoing research into disease-modifying therapies. Current research also focuses on the potential for combined therapies and personalized medicine approaches based on genetic factors.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "80 years old came with concerns of his memory function as he is forgetting names of the people and forgetting where he is putting his stuff; he is totally independent. What is the diagnosis?",
    "option_a": "Alzheimer disease.",
    "option_b": "Normal Aging",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Distinguishing between normal age\u2013related memory changes and pathological cognitive decline such as Alzheimer\u2019s disease is essential. Normal aging includes some degree of forgetfulness that does not significantly impair functional independence. Normal aging is associated with gradual cognitive changes including variable processing speed and occasional memory lapses. Unlike Alzheimer\u2019s, these changes are not due to extensive neurodegenerative processes but rather reflect the physiological aging of neural circuits. An 80-year-old who occasionally forgets names or misplaces items but remains fully independent in daily activities is consistent with normal aging rather than a neurodegenerative disorder. In Alzheimer\u2019s disease, memory impairment compromises daily functioning and interferes with complex tasks. Assessment includes a detailed history, cognitive screening tests (e.g., MMSE, MoCA), and evaluation of daily functional abilities. Differential diagnoses include mild cognitive impairment (MCI) and Alzheimer\u2019s disease. Clinicians rule out pathological conditions by confirming that the cognitive changes do not interfere with independent living. Management of normal aging involves reassurance, cognitive engagement, physical exercise, and lifestyle modifications. No pharmacological treatment is necessary for normal aging. In the context of pregnancy or lactation (though not typical in an 80-year-old), the emphasis would remain on non-pharmacological interventions. Option A (Alzheimer disease) is incorrect because Alzheimer\u2019s involves significant functional impairment. Option B (Normal Aging) is correct given the patient\u2019s independent functioning despite mild forgetfulness. 1. Occasional memory lapses in the elderly are common and do not necessarily indicate dementia. 2. Functional independence is a key marker to differentiate normal aging from neurodegenerative conditions. 3. Non-pharmacologic measures such as cognitive exercises and lifestyle interventions are central to management. Recent guidelines emphasize careful assessment to differentiate normal aging from MCI and early dementia, avoiding unnecessary pharmacological treatment. A holistic approach, including exercise and cognitive training, is increasingly recommended based on recent studies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Alzheimer patient, what is his CSF results:",
    "option_a": "low Amyloid B, High Tau",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Cerebrospinal fluid (CSF) biomarkers have become an important adjunct in the diagnosis of Alzheimer\u2019s disease. The typical profile includes low levels of beta-amyloid (particularly A\u03b242) and elevated levels of tau proteins. In Alzheimer\u2019s disease, beta-amyloid is sequestered into plaques within the brain, leading to decreased levels of A\u03b242 in the CSF. Concurrently, neuronal damage results in the release of tau and phosphorylated tau into the CSF, reflecting the degree of neurodegeneration. This CSF profile\u2014low amyloid beta and high total tau\u2014is characteristic of Alzheimer\u2019s disease and helps differentiate it from other neurodegenerative disorders. It correlates with the extent of plaque burden and neuronal injury seen on imaging. CSF analysis is used in conjunction with clinical assessment and neuroimaging to increase diagnostic accuracy, especially in atypical or early cases. Differential diagnoses include other causes of dementia, such as frontotemporal dementia (which may have a different CSF profile) and vascular dementia. While CSF biomarkers are primarily diagnostic and prognostic rather than used for direct management, their assessment can guide therapeutic decisions. Management still focuses on symptomatic treatment with cholinesterase inhibitors and NMDA receptor antagonists, along with supportive care. In pregnant or lactating women, lumbar puncture is generally safe but is reserved for cases where the diagnostic benefit outweighs the risks. Option A (low Amyloid B, High Tau) is correct because it accurately reflects the typical CSF biomarker pattern seen in Alzheimer\u2019s disease. Other patterns such as high amyloid or low tau would not be consistent with Alzheimer\u2019s pathology. 1. CSF biomarkers are powerful tools in supporting an Alzheimer\u2019s diagnosis, especially when clinical findings are ambiguous. 2. A low A\u03b242 combined with high tau levels is strongly indicative of Alzheimer\u2019s disease. 3. The ATN framework is increasingly used in both research and clinical settings to classify Alzheimer\u2019s pathology. Recent studies and updated guidelines, including those from the National Institute on Aging and Alzheimer\u2019s Association, continue to validate CSF biomarker profiles as critical components in the diagnostic workup of Alzheimer\u2019s disease, with research ongoing into their potential roles in monitoring disease progression and response to emerging therapies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Prosopagnosia localization?",
    "option_a": "Frontal lobe",
    "option_b": "Prietal lobe",
    "option_c": "corbus collosum",
    "option_d": "Occipital lobe (No temporal lobe in the choices)",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "Prosopagnosia is a form of visual agnosia characterized by an inability to recognize faces despite intact primary visual function. It is classically associated with damage to brain regions involved in processing complex visual stimuli such as faces. The syndrome most often results from damage to the fusiform face area (FFA), which is part of the ventral occipitotemporal cortex. Although the FFA is typically described as lying in the inferior temporal lobe, it is anatomically continuous with the lateral-occipital region. When the listed options exclude the temporal lobe, the occipital lobe (representing the posterior visual processing regions) is the next best available choice. Modern imaging studies have confirmed that lesions in the posterior (occipitotemporal) regions are the most common cause of acquired prosopagnosia. Patients with prosopagnosia may fail to recognize even close family members\u2019 faces, which can lead to significant social and emotional challenges. The deficit is selective; other aspects of visual perception (like object recognition) are typically preserved. Diagnosis is primarily clinical \u2013 based on the patient\u2019s history and neuropsychological testing \u2013 with confirmation by neuroimaging (typically MRI) to identify lesions in the fusiform gyrus or surrounding occipitotemporal cortex. Differential diagnoses include other visual agnosias and right hemisphere lesions affecting complex visual integration. There is no specific pharmacological treatment; management centers on compensatory strategies, rehabilitation, and environmental modifications. Cognitive and occupational therapies are used to help patients develop alternative ways to recognize individuals. In cases related to stroke, management of risk factors is also critical. (Pregnancy and lactation considerations are generally not applicable due to the typical patient population; however, when employed in younger patients, non-pharmacological rehabilitation remains first\u2010line.) A. Frontal lobe \u2013 Not involved in the specialized processing of faces; B. Parietal lobe \u2013 Typically associated with spatial processing and attention, not face recognition; C. Corpus callosum \u2013 Involved in interhemispheric transfer but not in detailed visual processing; D. Occipital lobe \u2013 Although the ideal answer would be a temporal lobe region (i.e., the fusiform gyrus), given the options, the occipital lobe (especially its ventral portion contiguous with the fusiform area) is the best answer. 1. Prosopagnosia is most commonly acquired after bilateral lesions of the fusiform gyrus. 2. Patients may still be able to recognize individuals using non-facial cues such as voices or gait. 3. A careful history and targeted neuroimaging are key to diagnosis. Recent neuroimaging research continues to reinforce the role of the ventral occipitotemporal cortex in facial recognition. In exam scenarios where temporal lobe options are absent, selecting the occipital lobe (encompassing the broader visual processing streams) is supported by the evidence.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]